Oli is an associate in our Cambridge office and is part of the Corporate Technology team.

Oli advises a range of companies in the tech and life sciences sectors on a variety of corporate matters, including venture capital investments, fundraisings, M&A and joint ventures.

Show full CV Hide full CV

Latest news & insights

Explaining strategy
Corporate/M&A & capital markets

Nuclera raises additional capital for eProtein™ desktop bioprinter to close Series B funding at $58 million

14 July 2022

by multiple authors

Click here to find out more
Handshake
Corporate/M&A & capital markets

Advising Placid0 on its acquisition by eyecare brand WALDO

25 February 2022

by multiple authors

Click here to find out more
Cyan lights fibre optic cable
Life sciences & healthcare

Advising Nuclera on its Series B funding round

2 February 2022

by multiple authors

Click here to find out more
Steel safe door
Corporate/M&A & capital markets

Advising Cambridge Epigenetix on its $88 million Series D funding round to advance best-in-class DNA sequencing technology platform

2 November 2021

by Ross McNaughton and Oli Denne

Click here to find out more

Related people

Meet me at

There are no upcoming events